MINI FUTURE SHORT - NOVO-NORDISK B | Real-time Bid/Ask 08:15:56 2024-05-31 EDT | ||
| 0.49 CHF / 0.5 CHF | -13.16% |
|
| Current month | -26.92% | ||
| 1 month | -26.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.57 | -3.39% |
| 24-05-29 | 0.59 | +3.51% |
| 24-05-28 | 0.57 | +3.64% |
| 24-05-27 | 0.55 | +14.58% |
| 24-05-24 | 0.48 | +11.63% |
Delayed Quote Swiss Exchange
Last update May 30, 2024 at 11:20 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| VKDABP | |
| ISIN | CH1332890867 |
| Date issued | 2024-03-07 |
| Strike | 1,003 kr |
| Maturity | Unlimited |
| Parity | 20 : 1 |
| Emission price | - CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.01 CHF |
|---|---|
| Lowest since issue | 0.43 CHF |
| Spread | 0.01 CHF |
| Spread % | 2.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
916.9
DKK
Average target price
917.2
DKK
Spread / Average Target
+0.04%
- Stock Market
- Certificates
- VKDABP Certificat
